Role of RNA-binding protein 5 in the diagnosis and chemotherapeutic response of lung cancer

Lung cancer remains one of the leading causes of cancer-associated mortality in the world. Lung carcinogenesis is frequently associated with deletions or the loss of heterozygosity at the critical chromosomal region 3p21.3, where RNA-binding protein 5 (RBM5) is localized. RBM5 regulates cell growth,...

Full description

Saved in:
Bibliographic Details
Published inOncology letters Vol. 17; no. 2; pp. 2013 - 2019
Main Authors Xu, Yanling, Su, Zhenzhong, Li, Junyao, Wang, Qi, Meng, Guangping, Zhang, Yu, Yang, Wen, Zhang, Jie, Gao, Peng
Format Journal Article
LanguageEnglish
Published Greece Spandidos Publications 01.02.2019
Spandidos Publications UK Ltd
D.A. Spandidos
Subjects
Apoptosis
Cancer diagnosis
Cancer patients
Cancer treatment
Carcinogenesis
Care and treatment
Cell cycle
Cell growth
Chemotherapy
Chromosomes
Development and progression
DNA methylation
Drug resistance
Gene expression
Genetic aspects
Health aspects
Homeostasis
Innovations
Kinases
Lung cancer
Medical diagnosis
Molecular targeted therapy
Mutation
Oncology
Protein binding
Respiratory system agents
Review
RNA
Transcription factors
Tumors
lung cancer
molecular target therapy
RNA-binding motif 5
biomarker
Online AccessGet full text

Cover

More Information
Summary:Lung cancer remains one of the leading causes of cancer-associated mortality in the world. Lung carcinogenesis is frequently associated with deletions or the loss of heterozygosity at the critical chromosomal region 3p21.3, where RNA-binding protein 5 (RBM5) is localized. RBM5 regulates cell growth, cell cycle progression and apoptosis in cell homeostasis. In the lungs, altered RBM5 protein expression leads to alterations in cell growth and apoptosis, with subsequent lung pathogenesis and varied responses to treatment in patients with lung cancer. Detection of RBM5 expression may be a tumor marker for diagnosis, prediction and treatment response in lung cancer, and may be developed as a potential therapeutic target for drug resistant lung cancer. This review discusses the most recent progress on the role of RBM5 in lung cancer.
ISSN:1792-1074
1792-1082
DOI:10.3892/ol.2018.9818